NASDAQ: $BCRX A Milestone for HAE Patients BioCryst Pharmaceuticals has reached a significant milestone in the management of Hereditary Angioedema (HAE). The U.S. Food and Drug Administration (FDA) has officially approved Orladeyo (berotralstat) 150 mg oral pellets. This approval provides a new, convenient treatment option for adults and adolescents aged 12 years and older looking…